Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MPN updates: trial updates, combinations & novel therapies

Ruben Mesa • 7 Dec 2019
ASH 2019
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases CPI-0610 Fedratinib Interferon Luspatercept Momelotinib Pacritinib Pomalidomide Ruxolitinib

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, highlights the key updates in myeloproliferative neoplasms (MPNs) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Ruben Mesa

2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
2:08
Real-world analysis of the MOST study: factors impacting progression to MF in patients with ET
Ruben Mesa • 9 Dec 2023
2:26
Assessing the impact of momelotinib on transfusion burden in MF: analysis of SIMPLIFY-1 & MOMENTUM
Ruben Mesa • 9 Dec 2023
2:20
Quantifying the anemia benefit of momelotinib in MF: analysis of data from SIMPLIFY-1 & SIMPLIFY-2
Ruben Mesa • 9 Dec 2023

Related Videos

1:13
The current BSH guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Mary Frances McMullin • 28 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
4:32
Current trials in MPN in the UK and the launch of the My MPN Voice app
Claire Harrison • 29 Apr 2024
2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals